The long pentraxin PTX3: A paradigm for humoral pattern recognition molecules

Annals of the New York Academy of Sciences

Volumn 1285, Issue 1, 2013, Pages 1-14

  Mantovani, Alberto ^a,b   Valentino, Sonia ^a   Gentile, Stefania ^a   Inforzato, Antonio ^a   Bottazzi, Barbara ^a   Garlanda, Cecilia ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Innate immunity; Pattern recognition molecules; Pentraxins; PTX3

Indexed keywords

ACUTE PHASE PROTEIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT FACTOR H; FATTY ACID BINDING PROTEIN; FC RECEPTOR; FICOLIN; GLUCOCORTICOID; LECTIN; MYELOID DIFFERENTIATION FACTOR 88; OPSONIN; PENTRAXIN 3; SERUM AMYLOID P; TROPONIN T;

AMINO ACID SEQUENCE; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT LECTIN PATHWAY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DENGUE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE SUBFERTILITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC CONSERVATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HEART FAILURE; HEMAGGLUTINATION; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INFLUENZA VIRUS A; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE INFECTION; LEPTOSPIROSIS; LIGAND BINDING; MENINGOCOCCOSIS; MOLECULAR RECOGNITION; MYXOSARCOMA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEINURIA; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 84878196475     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12043     Document Type: Article

References (140)

1. Jeannin, P. et al. 2005. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 22: 551-560.
2. Ip, W.K.E., K. Takahashi, K.J. Moore, et al. 2008. Mannose-binding lectin enhances Toll-like receptors 2 and 6 signaling from the phagosome. J. Exp. Med. 205: 169-181.
3. Holmskov, U., S. Thiel & J.C. Jensenius 2003. Collectins and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 21: 547-578.
4. Endo, Y., M. Matsushita & T. Fujita 2007. Role of ficolin in innate immunity and its molecular basis. Immunobiology 212: 371-379.
5. Garlanda, C., B. Bottazzi, A. Bastone & A. Mantovani 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition and female fertility. Annu. Rev. Immunol. 23: 337-366.
6. Abernethy, T.J. & O.T. Avery 1941. The occurence during acute infections of a protein non normally present in the blood. J. Exp. Med. 73: 173-182.
7. Casas, J.P., T. Shah, A.D. Hingorani, et al. 2008. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med. 264: 295-314.
8. Bottazzi, B., A. Doni, C. Garlanda & A. Mantovani 2010. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28: 157-183.
9. Emsley, J. et al. 1994. Structure of pentameric human serum amyloid P component. Nature 367: 338-345.
10. Shrive, A.K., A.M. Metcalfe, J.R. Cartwright & T.J. Greenhough 1999. C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP. J. Mol. Biol. 290: 997-1008.
11. Armstrong, P.B. et al. 1996. A cytolytic function for a sialic acid-binding lectin that is a member of the pentraxin family of proteins. J. Biol. Chem. 271: 14717-14721.
12. Liu, T.Y., F.A. Robey & C.M. Wang 1982. Structural studies on C-reactive protein. Ann. N.Y. Acad. Sci USA 389: 151-162.
13. Pepys, M.B. & G.M. Hirschfield 2003. C-reactive protein: a critical update. J. Clin. Invest. 111: 1805-1812.
14. Rubio, N., P.M. Sharp, M. Rits, et al. 1993. Structure, expression, and evolution of guinea pig serum amyloid P component and C-reactive protein. J. Biochem. 113: 277-284.
15. Pepys, M.B. et al. 1994. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. USA 91: 5602-5606.
16. Weiss, N.G., J.W. Jarvis, R.W. Nelson & M.A. Hayes 2011. Examining serum amyloid P component microheterogeneity using capillary isoelectric focusing and MALDI-MS. Proteomics 11: 106-113.
17. Roumenina, L.T. et al. 2006. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 45: 4093-4104.
18. Ng, P.M. et al. 2007. C-reactive protein collaborates with plasma lectins to boost immune response against bacteria. EMBO J. 26: 3431-3440.
19. Tanio, M., K. Wakamatsu & T. Kohno 2009. Binding site of C-reactive protein on M-ficolin. Mol. Immunol. 47: 215-221.
20. Jarva, H., T.S. Jokiranta, J. Hellwage, et al.1999. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J. Immunol. 163: 3957-3962.
21. Mihlan, M., S. Stippa, M. Jozsi & P.F. Zipfel 2009. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 16: 1630-1640.
22. Okemefuna, A.I., R. Nan, A. Miller, et al. 2010. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem. 285: 1053-1065.
23. Sjoberg, A.P., L.A. Trouw, F.D. McGrath, et al. 2006. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J. Immunol. 176: 7612-7620.
24. Garcia de Frutos, P., Y. Hardig & B. Dahlback 1995. Serum amyloid P component binding to C4b-binding protein. J. Biol. Chem. 270: 26950-26955.
25. Nauta, A.J., M.R. Daha, C. van Kooten & A. Roos 2003. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 24: 148-154.
26. Bharadwaj, D., C. Mold, E. Markham & T.W. Du Clos 2001. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J. Immunol. 166: 6735-6741.
27. Bharadwaj, D., M.P. Stein, M. Volzer, et al. 1999. The major receptor for C-reactive protein on leukocytes is Fc-gamma receptor II. J. Exp. Med. 190: 585-590.
28. Mold, C., R. Baca & T.W. Du Clos 2002. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fc-gamma receptors. J. Autoimmun. 19: 147-154.
29. Lu, J. et al. 2008. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 456: 989-992.
30. Szalai, A.J. 2002. The antimicrobial activity of C-reactive protein. Microb. Infect. 4: 201-205.
31. Szalai, A.J., D.E. Briles & J.E. Volanakis 1995. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J. Immunol. 155: 2557-2563.
32. Hind, C.R., P.M. Collins, M.L. Baltz & M.B. Pepys 1985. Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4, 6-pyruvate acetal of galactose. Interactions with various bacteria. Biochem. J. 225: 107-111.
33. Noursadeghi, M. et al. 2000. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc. Natl. Acad. Sci. USA 97: 14584-14589.
34. Andersen, O. et al. 1997. Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro. Scand. J. Immunol. 46: 331-337.
35. de Haas, C.J. et al. 2000. Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide- mediated classical pathway complement activation. Infect. Immun. 68: 1753-1759.
36. Horvath, A. et al. 2001. Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies. Antiviral Res. 52: 43-53.
37. Suresh, M.V., S.K. Singh, D.A. Ferguson, Jr. & A. Agrawal 2007. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J. Immunol. 178: 1158-1163.
38. Szalai, A.J., J.L. VanCott, J.R. McGhee, et al. 2000. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect. Immun. 68: 5652-5656.
39. Breviario, F. et al. 1992. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J. Biol. Chem. 267: 22190-22197.
40. Inforzato, A. et al. 2011. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens 77: 271-282.
41. Doni, A. et al. 2003. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur. J. Immunol. 33: 2886-2893.
42. Perrier, P. et al. 2004. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13. J. Immunol. 172: 7031-7042.
43. Mantovani, A., S.K. Biswas, M.R. Galdiero, et al. 2013. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229: 176-185.
44. Norata, G.D. et al. 2009. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708.
45. Salio, M. et al. 2008. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 117: 1055-1064.
46. Doni, A. et al. 2008. Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and non-hematopoietic cells. J. Biol. Chem. 283: 29983-29992.
47. Basile, A. et al. 1997. Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J. Biol. Chem. 272: 8172-8178.
48. Altmeyer, A., L. Klampfer, A.R. Goodman & J. Vilcek 1995. Promoter structure and transcriptional activation of the murine TSG-14 gene encoding a tumor necrosis factor/interleukin-1-inducible pentraxin protein. J. Biol. Chem. 270: 25584-25590.
49. Han, B. et al. 2005. TNF-alpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J. Immunol. 175: 8303-8311.
50. Norata, G.D. et al. 2008. Long pentraxin 3: a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28: 925-931.
51. Liangos, O. et al. 2010. Whole blood transcriptomics in cardiac surgery identifies a gene regulatory network connecting ischemia reperfusion with systemic inflammation. PloS One 5: e13658.
52. Willeke, F. et al. 2006. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur. J. Cancer 42: 2639-2646.
53. Germano, G. et al. 2010. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70: 2235-2244.
54. Inforzato, A. et al. 2006. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry 45: 11540-11551.
55. Introna, M. et al. 1996. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 87: 1862-1872.
56. Goodman, A.R. et al. 1996. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev. 7: 191-202.
57. Inforzato, A. et al. 2008. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J. Biol. Chem. 283: 10147-10161.
58. Presta, M., M. Camozzi, G. Salvatori & M. Rusnati 2007. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol. Med. 11: 723-738.
59. Inforzato, A. et al. 2010. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J. Biol. Chem. 285: 17681-17692.
60. Garlanda, C. et al. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420: 182-186.
61. Diniz, S.N. et al. 2004. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J. Leukoc. Biol. 75: 649-656.
62. Bozza, S. et al. 2006. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108: 3387-3396.
63. Reading, P.C. et al. 2008. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J. Immunol. 180: 3391-3398.
64. Gout, E. et al. 2011. M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J. Immunol. 186: 5815-5822.
65. Ma, Y.J. et al. 2009. Synergy between ficolin-2 and PTX3 boost innate immune recognition and complement deposition. J. Biol. Chem. 284: 28263-28275.
66. Ma, Y.J. et al. 2011. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J. Biol. Chem. 286: 3405-3417.
67. Braunschweig, A. & M. Jozsi 2011. Human pentraxin 3 binds to the complement regulator C4b-binding protein. PloS One 6: e23991.
68. Deban, L. et al. 2008. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J. Immunol. 181: 8433-8440.
69. Dias, A.A. et al. 2001. TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J. Leukoc. Biol. 69: 928-936.
70. Ravizza, T. et al. 2001. Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience 105: 43-53.
71. Deban, L. et al. 2010. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat. Immunol. 11: 328-334.
72. Rusnati, M. et al. 2004. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 104: 92-99.
73. Camozzi, M. et al. 2005. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler. Thromb. Vasc. Biol. 25: 1837-1842.
74. Salustri, A. et al. 2004. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 131: 1577-1586.
75. Scarchilli, L. et al. 2007. PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J. Biol. Chem. 282: 30161-30170.
76. Camozzi, M. et al. 2006. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J. Biol. Chem. 281: 22605-22613.
77. Jaillon, S. et al. 2007. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J. Exp. Med 204: 793-804.
78. Gaziano, R. et al. 2004. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob. Agents Chemother. 48: 4414-4421.
79. D'Angelo, C. et al. 2009. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J. Immunol. 183: 4609-4618.
80. Moalli, F. et al. 2010. Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood 116: 5170-5180.
81. Bottazzi, B. et al. 1997. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J. Biol. Chem. 272: 32817-32823.
82. Lu, J., K.D. Marjon, C. Mold, et al. 2012. Pentraxins and Fc receptors. Immunol. Rev. 250: 230-238.
83. Moalli, F. et al. 2011. The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J. Immunol. 186: 5425-5434.
84. Soares, A.C. et al. 2006. Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microb. Infect. 8: 1321-1329.
85. Job, E.R. et al. 2010. Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J. Immunol. 185: 4284-4291.
86. Olesen, R. et al. 2007. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tubercolosis risk in West-Africans. Genes Imm. 8: 456-467.
87. Chiarini, M. et al. 2010. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immu. 11: 665-670.
88. Han, B. et al. 2012. Protective effects of long pentraxin PTX3 on lung injury in a severe acute respiratory syndrome model in mice. Lab Invest. 92: 1285-1296.
89. Abraham, R. et al. 1995. Modulation of immunogenicity and antigenicity of proteins by maleylation to target scavenger receptors on macrophages. J. Immunol. 154: 1-8.
90. Jeannin, P., S. Jaillon & Y. Delneste 2008. Pattern recognition receptors in the immune response against dying cells. Curr. Opin. Immunol. 20: 530-537.
91. Gershov, D., S. Kim, N. Brot & K.B. Elkon 2000. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192: 1353-1364.
92. Baruah, P. et al. 2006. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J. Leukoc. Biol. 80: 87-95.
93. van Rossum, A.P. et al. 2004. The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum. 50: 2667-2674.
94. Rovere, P. et al. 2000. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96: 4300-4306.
95. Jaillon, S. et al. 2009. Endogenous PTX3 translocates at the membrane of late apoptotic human neutrophils and is involved in their engulfment by macrophages. Cell Death Differ. 16: 465-474.
96. Lech, M. et al. 2011. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PloS One 6: e20118.
97. Poon, I.K., M.D. Hulett & C.R. Parish 2010. Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ. 17: 381-397.
98. Trouw, L.A. et al. 2007. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J. Biol. Chem. 282: 28540-28548.
99. Biagi, E. et al. 2008. PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. J. Pediatr. Hematol. Oncol. 30: 881-885.
100. Sprong, T. et al. 2009. Ptx3 and C-reactive protein in severe meningococcal disease. Shock 31: 28-32.
101. Mairuhu, A.T. et al. 2005. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J. Med. Virol. 76: 547-552.
102. Azzurri, A. et al. 2005. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microb. Infect. 7: 1-8.
103. Wagenaar, J.F. et al. 2009. Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. J. Infect. 58: 425-432.
104. Muller, B. et al. 2001. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit. Care Med. 29: 1404-1407.
105. Peri, G. et al. 2000. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636-641.
106. Latini, R. et al. 2004. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354.
107. Jenny, N.S., A.M. Arnold, L.H. Kuller, et al. 2009. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 29: 594-599.
108. Ishino, M. et al. 2008. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ. J. 72: 1800-1805.
109. Kotooka, N. et al. 2008. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int. J. Cardiol. 130: 19-22.
110. Latini, R. et al. 2012. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur. J. Heart Failure 14: 992-999.
111. Kotooka, N. et al. 2008. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197: 368-374.
112. Naito, Y. et al. 2010. Increase in tissue and circulating pentraxin 3 levels in patients with aortic valve stenosis. Am. Heart J. 160: 685-691.
113. Inoue, K. et al. 2007. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler. Thromb. Vasc. Biol. 27: 161-167.
114. Matsui, S. et al. 2010. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 210: 220-225.
115. Hollan, I. et al. 2010. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res. 62: 378-385.
116. Ohbayashi, H. et al. 2009. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J. Atheroscler. Thromb. 16: 490-500.
117. Knoflach, M. et al. 2012. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY studies. PloS One 7: e31474.
118. Luchetti, M.M. et al. 2000. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin. Exp. Immunol. 119: 196-202.
119. Iwata, Y. et al. 2009. Increased serum pentraxin 3 in patients with systemic sclerosis. J. Rheumatol. 36: 976-983.
120. Fazzini, F. et al. 2001. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 44: 2841-2850.
121. Baldini, M. et al. 2011. Selective upregulation of the soluble pattern recognition receptor PTX3 and of VEGF in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 64: 854-865.
122. Mauri, T. et al. 2010. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intens. Care Med. 36: 621-629.
123. Mauri, T. et al. 2008. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit. Care Med. 36: 2302-2308.
124. Zanetti, M. et al. 2009. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin. Exp. Med. 9: 243-248.
125. Miyaki, A. et al. 2010. Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility? J. Atheroscler. Thromb. 17: 278-284.
126. Ogawa, T. et al. 2010. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity 18: 1871-1874.
127. Kato, S. et al. 2008. Increased expression of long pentraxin PTX3 in inflammatory bowel diseases. Dig. Dis. Sci. 53: 1910-1916.
128. Savchenko, A.S. et al. 2011. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol. Int. 61: 290-297.
129. Ryu, W.-S. et al. 2012. Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 220: 581-586.
130. Zanier, E. et al. 2011. Cerebrospinal fluid pentraxin 3 early after subarachnoid hemorrhage is associated with vasospasm. Intens. Care Med. 37: 302-309.
131. Suliman, M.E. et al. 2008. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3: 976-985.
132. Tong, M.C., J. Qureshi, A.R. Anderstam, et al. 2007. Plasma Pentraxin 3 in chronic kidney disease patients: association with renal function, protein-energy wasting, cardiovascular disease and mortality. Clin. J. Am. Soc. Nephrol. 2: 889-897.
133. Yilmaz, M.I. et al. 2011. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 6: 785-792.
134. Planque, C. et al. 2009. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol. Cell. Proteom. 8: 2746-2758.
135. Diamandis, E.P., L. Goodglick, C. Planque & M.D. Thornquist 2011. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. 17: 2395-2399.
136. Barbui, T. et al. 2011. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96: 315-318.
137. Tothill, R.W. et al. 2008. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14: 5198-5208.
138. Ravenna, L. et al. 2009. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 69: 1245-1255.
139. Wang, J.X., Y.L. He, S.T. Zhu, et al. 2011. Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J. Gastroenterol. 17: 4225-4230.
140. Lech, M. et al. 2013. Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int. Jan 16. DOI: 10.1038/ki.2012.463. [Epub ahead of print].